Eli Lilly reports exploratory Phase 3b results on combining Taltz and Zepbound in adults with psoriasis and obesity

Eli Lilly is advancing the clinical discussion around how obesity and immune-driven disease may connect, announcing new exploratory Phase 3b data involving the company’s psoriasis treatment Taltz and its weight-loss drug Zepbound. In a release carried by Yahoo Finance, Lilly said it presented findings tied to TOGETHER-PsO, a Phase 3b trial designed to evaluate the concomitant use of Taltz and Zepbound in adults with both psoriasis and obesity.

Taltz, generically ixekizumab, is a monoclonal antibody that targets an immune indicating pathway associated with inflammatory skin disease. Zepbound, generically tirzepatide, is a metabolic therapy intended for weight management, using activity on hormone receptors involved in appetite and glucose regulation. Lilly’s study combines the two classes to test whether addressing metabolic biology alongside immune inflammation can change outcomes in people who have both conditions.

The TOGETHER-PsO trial is described as evaluating the combination of Taltz and Zepbound against a comparator of Taltz alone. Lilly framed the work not only as a clinical question about concomitant therapy, but also as a way to deepen scientific understanding of interconnected immune and metabolic biology. That framing matters because psoriasis is widely understood as an immune-mediated disease, while obesity is associated with chronic inflammation and changes in metabolic indicating that can influence immune function.

In the company’s announcement, the new data are characterized as “exploratory.” Lilly did not, in the information provided here, specify the magnitude of any clinical effects or safety indicates, nor did it outline which endpoints were most affected. Without those details, it is not possible to determine from the published report whether the exploratory findings represent statistically significant improvements in key measures of psoriasis control, weight loss, or other disease-related biomarkers.

Lilly’s choice to run an exploratory Phase 3b trial suggests it is treating the combination question as both a patient-focused development effort and a mechanistic research opportunity. For companies working in immunology and metabolic disease, combination studies can also help clarify whether clinically meaningful benefits come from immune pathway modulation, metabolic pathway changes, or some interaction between the two. If future datasets support a consistent relationship, that could influence how clinicians think about comanagement of inflammatory disease in patients with excess weight.

Still, the publicly shared material in the cited report offers limited granularity. The announcement, as reflected in the Yahoo Finance write-up, does not provide specific results such as responder rates, effect sizes, or detailed adverse event summaries. The company also does not appear to have disclosed in the information presented here the exact timing of the analysis, the number of participants analyzed for these exploratory outcomes, or whether the study included prespecified subgroup analyses. Those omissions leave key questions about the strength and clinical relevance of the findings unanswered at this stage.

What to watch next is whether Lilly will publish more complete trial readouts for TOGETHER-PsO, including predefined efficacy endpoints and safety outcomes for the combination arm versus Taltz alone. Additional disclosure on how metabolic changes from Zepbound relate to measures of immune activity in psoriasis would also help determine whether the company’s “interconnected biology” thesis translates into clear clinical impact for adults dealing with both obesity and skin inflammation.